If you’ve already registered, please click here to log in to the webcast.

Recent technological advancements have enabled the development of liquid biopsy-based approaches, which are revolutionizing the field of diagnostics. This webcast will highlight recent achievements facilitating the development of liquid biopsy-based tests in lung cancer and malignant glioma.

The analysis of circulating tumor DNA (ctDNA) holds numerous clinical applications, from widely used non-invasive biomarker testing to potential prognostic significance. The impact on lung cancer patients is noteworthy as obtaining biopsies can be challenging due to the anatomy of the tumor. Furthermore, monitoring ctDNA levels throughout the disease course can prove valuable for tracking tumor response to treatment and for early detection of resistance mutations. Lastly, enhancements in assay sensitivity could enable testing for minimal residual disease (MRD) measurement and, ultimately, for devising strategies (complementing imaging techniques) aimed at enhancing the efficacy of lung cancer screening programs.

In glioblastoma (GB), a highly aggressive central nervous system tumor with a dismal prognosis, liquid biopsy research is groundbreaking. O6-methylguanine-DNA methyltransferase (MGMT) methylation (mMGMT) stands as the sole well-established predictive and prognostic biomarker in GB, linked to enhanced treatment response and extended survival. Nevertheless, current methods for monitoring mMGMT status have fallen short. Now, small extracellular vesicles (sEVs) are a potential game-changer poised to revolutionize clinical diagnostics via liquid biopsy.

• Understanding tumor heterogeneity and identifying key biomarkers
• Liquid biopsy testing developments
• Clinical research and screening applications of liquid biopsies.